All News
The C-AxSpand study, Certolizumab-treated nr-axSpA pts with shorter symptom duration (< 5 vs ≥ 5 years) showed greater improvements across signs and symptoms of disease and in quality of life. Kay J et al #ACR19 @RheumNow
Dr. Antoni Chan synovialjoints ( View Tweet)
ACR 2018 - Day 1 Report
Highlights from Tuesday and Wednesday (days 3 and 4) from the ACR annual meeting include: the important and impactful abstracts covered by the Rheumatology Roundup session; upadacitinib clinical trials; and the baricitinib CV and VTE safety analysis.
Read Article
ACR 2018 - Day 1 Report
Highlights from Tuesday and Wednesday (days 3 and 4) from the ACR annual meeting include: the important and impactful abstracts covered by the Rheumatology Roundup session; upadacitinib clinical trials; and the baricitinib CV and VTE safety analysis.
Read Article
FEAR: A Perception of Fact In Spite of the Fiction
Pregnancy for patients with lupus has long been considered high risk and associated with both medical and obstetric complications, but outcomes have improved over the last 2 decades and continue to improve.
Read Article